Posted in | News | Packaging | Biomaterials

Stora Enso Invests to Build Facility for Bio-Based Plastic Packaging Material

Stora Enso has announced that it is investing EUR 9 million to build a pilot facility for enabling the production of bio-based plastics as barrier in transparent packaging. The pilot plant will convert plant-based sugars into the renewable building block required to make PEF, a bio-based plastic, mainly targeting the food and beverage industry. The pilot plant will be located at Stora Enso’s Langerbrugge Mill in Belgium.

Replacing Fossil-based Materials

The investment in bio-based chemistry further strengthens Stora Enso’s opportunities to replace fossil-based materials with renewable and recyclable materials. The pilot plant will focus on developing a cost-competitive process for manufacturing FDCA (furandicarboxylic acid) from sugars. FDCA is a key component of the bio-based barrier material PEF (polyethylene furanoate).

In addition to its renewable nature, PEF’s attractive barrier, mechanical and thermal properties open new packaging opportunities, such as small liquid containers for soft drinks, juices and other beverages.

Increased Need of Sustainable Packaging

Bio-based materials are of rapidly growing interest in the packaging world as companies look for sustainable packaging materials with high performance,” says Markus Mannström, Executive Vice President of Stora Enso’s Biomaterials division. “With this pilot, we continue to build on our long-term R&D work while targeting new markets with innovative, renewable materials that replace fossil-based materials. We believe that innovation does not happen in isolation. We are, therefore, looking forward to expanding our cooperation within the field of bio-based chemicals,” Mannström says.

Stora Enso’s pilot aims to validate the chemical process and provide sample material to gain further insight into market need and product demand. The pilot facility will initially use industrially available fructose to produce high-value chemicals and materials for application testing. In the future, the intention is to run the process on sugars extracted from wood and other non-food biomasses.

Stora Enso’s Biomaterials Division to Run the Project

The new pilot project will be run by Stora Enso’s Biomaterials division. The Langerbrugge paper mill provides space and infrastructure for hosting the facility. Also, the Ghent area in Belgium is home to many chemical production sites. The design and engineering of the pilot facility have started, and construction will begin in the second half of 2020.

The plant is estimated to be ready in the first quarter of 2021. Decisions about commercialization will follow evaluating the results of the pilot-scale production.
Stora Enso’s Langerbrugge Mill is one the largest paper mills in Europe, producing 540 000 tons of recycled newsprint and magazine papers annually. The production is exclusively based on paper for recycling. The pilot plant investment will not impact the mill’s paper production.



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Stora Enso. (2019, December 20). Stora Enso Invests to Build Facility for Bio-Based Plastic Packaging Material. AZoCleantech. Retrieved on May 24, 2024 from

  • MLA

    Stora Enso. "Stora Enso Invests to Build Facility for Bio-Based Plastic Packaging Material". AZoCleantech. 24 May 2024. <>.

  • Chicago

    Stora Enso. "Stora Enso Invests to Build Facility for Bio-Based Plastic Packaging Material". AZoCleantech. (accessed May 24, 2024).

  • Harvard

    Stora Enso. 2019. Stora Enso Invests to Build Facility for Bio-Based Plastic Packaging Material. AZoCleantech, viewed 24 May 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.